Aragen Life Sciences

Aragen Life Sciences, among the top three largest Indian CRDMOs, begins operations at Aragen OneHP, a high-potency development and manufacturing platform at its Nacharam campus in Hyderabad. The platform adds capabilities for highly potent molecules, incl

Aragen Life Sciences starts operations at its new 15,000 sq ft high-potency API manufacturing platform in Hyderabad, enhancing oncology drug development.

Hyderabad: Aragen Life Sciences has commenced operations at Aragen OneHP, a high-potency development and manufacturing platform at its Nacharam campus in Hyderabad, adding capabilities for highly...

Aragen Life Sciences launches OneHP high-potency development and manufacturing platform in Hyderabad

Aragen Life Sciences to begin operations at OneHP, an integrated platform in Hyderabad

In lead optimization, every compound progression decision depends on timely access to high-quality data. DMPK studies provide critical insights into a molecule's developability, helping teams determine which compounds should advance and which require furt

The ecosystem of drug development involves multiple interconnected activities that collectively enable integrated drug substance (DS) and drug product (DP) development. Along this continuum, several scientific disciplines must work in parallel, including

A promising therapeutic candidate eventually reaches a decisive moment: the in vivo study that will shape what happens next. At this stage, choosing a Contract Research Organization (CRO) may appear to be a decision about models, capabilities, timelines,

In drug discovery and development, critical decisions are only as good as the data supporting them. Whether selecting a lead candidate, validating a therapeutic target, or advancing a molecule into the next phase of development, researchers rely on protei

Peptide therapeutics continue to gain momentum across metabolic disorders, oncology, and other high-value therapeutic areas. However, for sponsors advancing peptide candidates toward the clinic, one question remains critical: Can preclinical pharmacokinet